|
|
楼主 |
发表于 2025-2-21 00:22:13
|
显示全部楼层
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中' F% Q n: ~& G D1 F$ v* }
Whole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)
. _! e: |6 Z$ t5 Y
4 w2 E8 j$ M( G2 [6 c* o6 PAdjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
9 G2 F$ W! }& l* _9 r% k' k
/ n4 |" V9 _5 H! B/ e0 t- GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)
- Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)
- Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中)
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)
- Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)
- Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
- Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中)4 k) Q# C1 f% {" g& i
" F) f8 B( Z) ~! H: E0 ]
|
|
[复制链接]
发表于 2025-2-20 09:21:40
